Dynavax (DVAX -13.4%) is down on increased volume in early trade in apparent response to the release of updated results from its ongoing Phase 1/2 study of SD-101 + Merck’s Keytruda (pembrolizumab) in PD-1-naive advanced melanoma patients.
In 25 subjects, the overall response rate was 60% (n=15/25). Preliminary data presented last year at ASCO (seven patients) showed a 100% response rate.
Previously: Combination of Dynavax’s SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours (June 2, 2017)
#ASCO18
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.